Status:
COMPLETED
Adverse Effects of ALA-PDT for the Treatment of Moderate to Severe Acne Vulgaris: a Prospective Study
Lead Sponsor:
Shanghai Dermatology Hospital
Conditions:
Acne Vulgaris
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To understand, prevent and treat the adverse reactions more comprehensively, we sought to systemically document the adverse effects of ALA-PDT for moderate to severe acne vulgaris.
Detailed Description
To understand, prevent and treat the adverse reactions more comprehensively, we sought to systemically document the adverse effects of ALA-PDT for moderate to severe acne vulgaris.
Eligibility Criteria
Inclusion
- (1) Patients diagnosed with moderate to severe acne and graded grade III-IV according to Investigator's Global Assessment (IGA) ;
- (2) Patients unsuitable for drug treatment owing to various reasons and who voluntarily participated and signed informed consent following information about other alternatives;
- (3) Patients who read the instructions and were willing to follow the program requirements.
Exclusion
- (1) Patients who had a history of photosensitive diseases;
- (2) Patients who had Modified-PDT;
- (3) Patients who had oral isotretinoin in the past 3 months, used oral contraceptives or antibiotics and underwent local or facial surgery in the past 4 weeks;
- (4) Female patients who were pregnant or lactating.
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04709289
Start Date
January 1 2020
End Date
February 28 2020
Last Update
January 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lei Shi
Shanghai, Shanghai Municipality, China, 200443